journal
MENU ▼
Read by QxMD icon Read
search

International Journal of Clinical Oncology

journal
https://www.readbyqxmd.com/read/28799063/clinical-outcomes-of-patients-with-epithelioid-sarcomas-impact-and-management-of-nodal-metastasis
#1
Hidetatsu Outani, Yoshinori Imura, Takaaki Tanaka, Satoshi Takenaka, Kazuya Oshima, Kenichiro Hamada, Shigeki Kakunaga, Susumu Joyama, Norifumi Naka, Ikuo Kudawara, Takafumi Ueda, Nobuhito Araki, Hideki Yoshikawa
PURPOSE: An epithelioid sarcoma is a rare histological subtype of a soft tissue sarcoma with a high local recurrence rate, which frequently shows lymph node metastasis. However, because of the rarity of this tumor, the impact of nodal metastasis and its appropriate management remain unclear. The present study investigated the clinical outcomes of patients with epithelioid sarcomas, with a focus on lymph node metastasis. METHODS: We retrospectively evaluated the clinical outcomes of 27 patients with epithelioid sarcomas treated between 1985 and 2015...
August 10, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28795280/the-use-of-neoadjuvant-therapy-for-resectable-locally-advanced-thoracic-esophageal-squamous-cell-carcinoma-in-an-analysis-of-5016-patients-from-305-designated-cancer-care-hospitals-in-japan
#2
Yoichiro Tsukada, Takahiro Higashi, Hideaki Shimada, Yoshinori Kikuchi, Atsuro Terahara
BACKGROUND: Recent studies have shown the benefits of neoadjuvant therapy with chemotherapy or chemoradiotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC). The aim of our study was to elucidate the use of neoadjuvant therapy for thoracic ESCC in Japan. METHODS: Data on patients with stage IB-III thoracic ESCC were retrieved from the national database of hospital-based cancer registries combined with claims data between 2012 and 2013...
August 9, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28791509/feasibility-of-dose-dense-epirubicin-and-cyclophosphamide-with-subcutaneous-pegfilgrastim-3-6%C3%A2-mg-support-a-single-center-prospective-study-in-japan
#3
Sachi Morita, Toyone Kikumori, Nobuyuki Tsunoda, Takahiro Inaishi, Yayoi Adachi, Akiko Ota, Masahiro Shibata, Ayumu Matsuoka, Kenichi Nakanishi, Dai Takeuchi, Takefumi Mizutani, Tomoya Shimokata, Hironori Hayashi, Osamu Maeda, Yuichi Ando
BACKGROUND: Dose-dense chemotherapy consisting of a combination of epirubicin and cyclophosphamide (EC) improves the survival of patients with breast cancer. Although pegfilgrastim was used at a subcutaneous dose of 6.0 mg in a pivotal study of dose-dense EC treatment, pegfilgrastim at a dose of 3.6 mg has been approved in Japan. We have assessed the feasibility of dose-dense EC treatment supported with a 3.6 mg dose of pegfilgrastim by evaluating the relative dose intensity (RDI) and safety of the treatment, together with measuring the pegfilgrastim concentrations remaining on the day of starting the next cycle of chemotherapy...
August 8, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28791497/low-preoperative-serum-cholesterol-level-is-associated-with-aggressive-pathologic-features-and-poor-cancer-specific-survival-in-patients-with-surgically-treated-renal-cell-carcinoma
#4
Ho Won Kang, Sung Pil Seo, Won Tae Kim, Seok Joong Yun, Sang-Cheol Lee, Wun-Jae Kim, Eu Chang Hwang, Seok Ho Kang, Sung-Hoo Hong, Jinsoo Chung, Tae Gyun Kwon, Hyeon Hoe Kim, Cheol Kwak, Seok-Soo Byun, Yong-June Kim
BACKGROUND: The prognostic implications of preoperative serum total cholesterol (TC) level in patients with renal cell carcinoma (RCC) remain poorly understood. We investigated the prognostic role of preoperative serum TC in patients with surgically treated RCC from a large, multi-institutional Korean collaboration. PATIENTS AND METHODS: A database of 3064 patients with RCC who underwent radical or partial nephrectomy between 1999 and 2011 at eight academic centers was analyzed...
August 8, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28770408/phase-ii-study-of-radium-223-dichloride-in-japanese-patients-with-symptomatic-castration-resistant-prostate-cancer
#5
Nobuaki Matsubara, Satsohi Nagamori, Yoshiaki Wakumoto, Hirotsugu Uemura, Go Kimura, Akira Yokomizo, Hiroaki Kikukawa, Atsushi Mizokami, Takeo Kosaka, Naoya Masumori, Yoshihide Kawasaki, Junji Yonese, Yasutomo Nasu, Satoshi Fukasawa, Takayuki Sugiyama, Seigo Kinuya, Makoto Hosono, Iku Yamaguchi, Hirokazu Tsutsui, Hiroji Uemura
BACKGROUND: Radium-223 dichloride (radium-223) is the first targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. This study investigated the efficacy and safety of radium-223 in Japanese patients with symptomatic CRPC and bone metastases. METHODS: In this open-label, multicenter, phase II study, patients with progressive, symptomatic CRPC and bone metastases were treated with radium-223 (55 kBq/kg, intravenously) in a 4-week cycle for six cycles...
August 2, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28758177/the-5-year-outcomes-of-moderately-hypofractionated-radiotherapy-66%C3%A2-gy-in-22-fractions-3-fractions-per-week-for-localized-prostate-cancer-a-retrospective-study
#6
Yaichiro Hashimoto, Atsushi Motegi, Tetsuo Akimoto, Norio Mitsuhashi, Junpei Iizuka, Kazunari Tanabe, Yuka Ishii, Sawa Kono, Sachiko Izumi, Kumiko Karasawa
BACKGROUND: Hypofractionated radiotherapy using fewer and larger fractional doses may be more beneficial than conventional external-beam radiotherapy for localized prostate cancer. We evaluated the 5-year outcomes of moderately hypofractionated radiotherapy for localized prostate cancer. METHODS: We retrospectively evaluated 195 patients with localized prostate cancer (T1-3N0M0) who underwent intensity-modulated radiotherapy (IMRT) (66 Gy delivered in fractions of 3 Gy every other weekday) between May 2005 and December 2011...
July 31, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28756594/decreased-acute-toxicities-of-intensity-modulated-radiation-therapy-for-localized-prostate-cancer-with-prostate-based-versus-bone-based-image-guidance
#7
Kiyonao Nakamura, Takashi Mizowaki, Haruo Inokuchi, Itaru Ikeda, Takahiro Inoue, Tomomi Kamba, Osamu Ogawa, Masahiro Hiraoka
BACKGROUND: Intensity-modulated radiation therapy (IMRT) is a major therapeutic option for localized prostate cancer. Image-guided radiation therapy (IGRT) allows tumor visualization and corrects the errors caused by daily internal movement of the prostate. The current study retrospectively compared the acute toxicities and biochemical tumor control outcomes of prostate IMRT achieved using two IGRT techniques: bony structure-based IGRT (B-IGRT) and prostate-based IGRT (P-IGRT). METHODS: Between February 2011 and July 2014, 96 patients with low- or intermediate-risk prostate cancer were treated using P-IGRT based on cone-beam computed tomography (CBCT; 76 Gy) without fiducial markers...
July 29, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28755069/erratum-to-sarcopenia-but-not-visceral-fat-amount-is-a-risk-factor-of-postoperative-complications-after-major-hepatectomy
#8
Takaaki Higashi, Hiromitsu Hayashi, Katsunobu Taki, Keita Sakamoto, Hideyuki Kuroki, Hidetoshi Nitta, Daisuke Hashimoto, Akira Chikamoto, Toru Beppu, Hideo Baba
No abstract text is available yet for this article.
July 28, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28752352/presurgical-axitinib-therapy-increases-fibrotic-reactions-within-tumor-thrombus-in-renal-cell-carcinoma-with-thrombus-extending-to-the-inferior-vena-cava
#9
Yoshimi Tanaka, Shingo Hatakeyama, Shogo Hosogoe, Toshikazu Tanaka, Itsuto Hamano, Ayumu Kusaka, Hiromich Iwamura, Naoki Fujita, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama
BACKGROUND: Clinical benefits of presurgical axitinib therapy for renal cell carcinoma (RCC) extending into the inferior vena cava (IVC) remain unclear. We aimed to investigate surgical benefits and pathological antitumor effects of presurgical axitinib therapy for RCC with IVC thrombus. METHODS: Of 56 consecutive RCC patients with IVC thrombus between January 1994 and December 2016, 41 patients who underwent radical nephrectomy (RN) were categorized as upfront RN (Upfront group) or presurgical axitinib followed by RN (Presurgical group)...
July 27, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28752351/the-clinical-use-of-neutrophil-to-lymphocyte-ratio-in-bladder-cancer-patients-a-systematic-review-and-meta-analysis
#10
REVIEW
Xingxing Tang, Peng Du, Yong Yang
The aim of this study was to evaluate the evidence regarding the neutrophil-to-lymphocyte ratio (NLR) as a factor predictive of survival in bladder cancer patients. A search of PubMed and Embase for relevant studies between January 1, 1966 and November 10, 2016 was performed with the terms [NLR OR (neutrophil lymphocyte ratio)] AND [(bladder cancer) OR BCa OR NMIBC OR MIBC]. Inclusion required studies published in English containing bladder cancer patients and evaluating NLR as a predictive factor. Endpoints of NLR and survival data were extracted for pooled analysis...
July 27, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28748356/pd-l1-induced-by-ifn-%C3%AE-from-tumor-associated-macrophages-via-the-jak-stat3-and-pi3k-akt-signaling-pathways-promoted-progression-of-lung-cancer
#11
Xiaohui Zhang, Yuanyuan Zeng, Qiuxia Qu, Jianjie Zhu, Zeyi Liu, Weiwei Ning, Hui Zeng, Nan Zhang, Wenwen Du, Cheng Chen, Jian-An Huang
BACKGROUND: Interferon-γ (IFN-γ) is conventionally regarded as an inflammatory cytokine that has a pivotal role in anti-infection and tumor immune surveillance. It has been used clinically to treat a variety of malignancies. However, increased evidence has suggested IFN-γ can act to induce tumor progression. The role of IFN-γ in regulating antitumor immunity appears to be complex and paradoxical. The mechanism underlying the dual aspects of IFN-γ function in antitumor immunity is not clear...
July 26, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28748355/retrospective-comparison-of-s-1-plus-cisplatin-versus-s-1-monotherapy-for-the-treatment-of-advanced-gastric-cancer-patients-with-positive-peritoneal-cytology-but-without-gross-peritoneal-metastasis
#12
Izuma Nakayama, Keisho Chin, Tomohiro Matsushima, Daisuke Takahari, Mariko Ogura, Eiji Shinozaki, Mitsukuni Suenaga, Masato Ozaka, Takeru Wakatsuki, Takashi Ichimura, Osumi Hiroki, Kensei Yamaguchi
BACKGROUND: Peritoneal cytology positive for carcinoma cells (CY+) is an independent poor prognostic factor in gastric cancer, and patients with CY+ are diagnosed with stage IV disease. However, there is no standard treatment strategy for CY+ gastric cancer, whereas combination chemotherapy with fluoropyrimidine and platinum has been established as the standard treatment for unresectable advanced gastric cancer or after R2 resection. Herein, we assessed whether adding cisplatin to S-1 (SP) could improve the outcome of CY+ gastric cancer patients, as compared to S-1 monotherapy...
July 26, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28744725/impact-of-major-different-variants-of-papillary-thyroid-microcarcinoma-on-the-clinicopathological-characteristics-the-study-of-1041-cases
#13
Jingtai Zhi, Jingzhu Zhao, Ming Gao, Yi Pan, Jianghua Wu, Yigong Li, Dapeng Li, Yang Yu, Xiangqian Zheng
BACKGROUND: The incidence of papillary thyroid microcarcinoma (PTMC) has been increasing globally in the past few decades. PTMC does not have a distinctive morphology that results in differences in biological behavior. The aim of this study was to classify PTMCs according to the morphological features and explore the relationship with clinicopathological characteristics. Additionally, we sought to evaluate whether different variants of PTMC can be an independent predictor for lymph mode metastasis when considering other risk factors...
July 25, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28744724/concordance-of-clinical-diagnosis-of-t-classification-among-physicians-for-locally-advanced-unresectable-thoracic-esophageal-cancer
#14
Tomoya Yokota, Takushi Yasuda, Hiroyuki Kato, Isao Nozaki, Hiroshi Sato, Yoshinori Miyata, Yoshifumi Kuroki, Ken Kato, Yasuo Hamamoto, Yasuhiro Tsubosa, Hirofumi Ogawa, Yoshinori Ito, Yuko Kitagawa
BACKGROUND: We conducted a multicenter phase II trial assessing chemoselection with docetaxel plus 5-fluorouracil and cisplatin induction chemotherapy and subsequent conversion surgery for locally advanced, unresectable esophageal cancer. The aim of this study was to validate the concordance of clinical T diagnosis among physicians in the cases of this trial. METHODS: Computed tomography scans and esophagoscopic images of 48 patients taken at baseline were centrally reviewed by 6 senior physicians with experience in esophageal oncology...
July 25, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28733795/early-response-of-c-reactive-protein-as-a-predictor-of-survival-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-tyrosine-kinase-inhibitors
#15
Yosuke Yasuda, Kazutaka Saito, Takeshi Yuasa, Sho Uehara, Naoko Kawamura, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Shinya Yamamoto, Tetsuo Okuno, Junji Yonese, Kazunori Kihara, Yasuhisa Fujii
BACKGROUND: Pretreatment C-reactive protein (CRP) has been shown to be an independent prognostic factor for metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs). We further evaluated the early response of CRP after the initiation of TKIs. METHODS: A total of 103 patients (80 men and 23 women) were treated with TKIs for mRCC from 2008-2013. Patients were divided into three groups according to their early CRP kinetics-patients whose baseline CRP levels were <10 mg/L (non-elevated), patients whose baseline CRP levels were ≥10 mg/L and had decreased by >20% at 4 weeks after the initiation of TKIs (early CRP responder), and the remaining patients (non-early CRP responder)...
July 21, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28733794/fatigue-associated-with-newly-approved-vascular-endothelial-growth-factor-receptor-tyrosine-kinase-inhibitors-in-cancer-patients-an-up-to-date-meta-analysis
#16
REVIEW
Jing Li, Jian Gu
The fatigue associated with five newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) (regorafenib, vandetanib, cabozantinib, lenvatinib, axitinib) is poorly understood. We conducted this systematic review to fully investigate the fatigue associated with these VEGFR-TKIs in cancer patients. Relevant studies of randomized controlled trials in cancer patients treated with the five VEGFR-TKIs were retrieved and a systematic evaluation was conducted. EMBASE, MEDLINE, and PubMed were searched for articles published until March 2017...
July 21, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28725937/aspirin-use-and-head-and-neck-cancer-survival-an-observational-study-of-11-623-person-years-follow-up
#17
Shin-Ae Kim, Jong-Lyel Roh, Sung-Bae Kim, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim
BACKGROUND: Acetylsalicylic acid (aspirin) and non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with reduced risks for certain human cancers. However, the effects of aspirin and NSAIDs on head and neck squamous cell carcinoma (HNSCC) remain controversial, and the prognostic effects of these drugs in patients with HNSCC are largely unknown. This study examined the clinical impact of aspirin and NSAIDs on disease recurrence and survival in patients with HNSCC. METHODS: This study analysed a cohort of 1392 consecutive patients who received definitive treatment for previously untreated HNSCC at our tertiary referral center...
July 19, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28717856/intraoperative-radiotherapy-for-extremity-soft-tissue-sarcomas-can-long-term-local-control-be-achieved
#18
Esther Carbó-Laso, Pablo Sanz-Ruiz, José Antonio Calvo-Haro, Miguel Cuervo-Dehesa, Rubén Pérez-Mañanes, Lydia Mediavilla-Santos, Coral Sánchez-Pérez, Ana Álvarez-González, Javier Vaquero-Martín
BACKGROUND: Intraoperative electron-beam radiation therapy (IOERT) during limb-sparing surgery has the advantage of delivering a single high boost dose to sarcoma residues and surgical bed area near to radiosensitive structures with limited toxicity. Retrospective studies have suggested that IOERT may improve local control compared to standard radiotherapy and we aimed to demonstrate this theory. Therefore, we performed an observational prospective study to determine (1) if it is possible to achieve high local control by adding IOERT to external-beam radiation therapy (EBRT) in extremity soft-tissue sarcomas (STS), (2) if it is possible to improve long-term survival rates, and (3) if toxicity could be reduced with IOERT MATERIALS AND METHODS: From 1995-2003, 39 patients with extremity STS were treated with IOERT and postoperative radiotherapy...
July 17, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28717855/esophageal-stenosis-and-the-glasgow-prognostic-score-as-independent-factors-of-poor-prognosis-for-patients-with-locally-advanced-unresectable-esophageal-cancer-treated-with-chemoradiotherapy-exploratory-analysis-of-jcog0303
#19
Tatsuya Okuno, Masashi Wakabayashi, Ken Kato, Masayuki Shinoda, Hiroshi Katayama, Hiroyasu Igaki, Yasuhiro Tsubosa, Takashi Kojima, Hiroshi Okabe, Yusuke Kimura, Tatsuyuki Kawano, Shinichi Kosugi, Yasushi Toh, Hoichi Kato, Kenichi Nakamura, Haruhiko Fukuda, Satoshi Ishikura, Nobutoshi Ando, Yuko Kitagawa
BACKGROUND: The aim of this study was to investigate the possible prognostic factors and predictive accuracy of the Glasgow Prognostic Score (GPS) for patients with unresectable locally advanced esophageal squamous cell carcinoma (LAESCC) treated with chemoradiotherapy. METHODS: One hundred forty-two patients were enrolled in JCOG0303 and assigned to the standard cisplatin and 5-fluorouracil (PF)-radiotherapy (RT) group or the low-dose PF-RT group. One hundred thirty-one patients with sufficient data were included in this analysis...
July 17, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28681153/overall-survival-of-high-risk-prostate-cancer-patients-who-received-neoadjuvant-chemohormonal-therapy-followed-by-radical-prostatectomy-at-a-single-institution
#20
Naoki Fujita, Takuya Koie, Chikara Ohyama, Yoshimi Tanaka, Osamu Soma, Teppei Matsumoto, Hayato Yamamoto, Atsushi Imai, Yuki Tobisawa, Tohru Yoneyama, Shingo Hatakeyama, Yasuhiro Hashimoto
BACKGROUND: The optimal treatment for high-risk prostate cancer (PCa) remains to be established. We previously reported favorable, biochemical recurrence-free survival in high-risk PCa patients treated with a neoadjuvant gonadotropin-releasing hormone agonist or antagonist and estramustine phosphate (EMP) (chemohormonal therapy; CHT) followed by radical prostatectomy (RP). We conducted a retrospective study to elucidate the clinical benefit of neoadjuvant CHT for high-risk PCa patients...
July 5, 2017: International Journal of Clinical Oncology
journal
journal
32641
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"